CN111511749A - 具有大环分子结构的化合物及其用途 - Google Patents

具有大环分子结构的化合物及其用途 Download PDF

Info

Publication number
CN111511749A
CN111511749A CN201980006719.7A CN201980006719A CN111511749A CN 111511749 A CN111511749 A CN 111511749A CN 201980006719 A CN201980006719 A CN 201980006719A CN 111511749 A CN111511749 A CN 111511749A
Authority
CN
China
Prior art keywords
compound
formula
present disclosure
fluorine
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980006719.7A
Other languages
English (en)
Other versions
CN111511749B (zh
Inventor
林菊芳
应永铖
廖敬礼
张秀
李宗然
袁纪军
贾伟
汪伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jibei Biotechnology Co ltd
Original Assignee
Shanghai Jibei Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jibei Biotechnology Co ltd filed Critical Shanghai Jibei Biotechnology Co ltd
Publication of CN111511749A publication Critical patent/CN111511749A/zh
Application granted granted Critical
Publication of CN111511749B publication Critical patent/CN111511749B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本公开涉及一种通式(I)所示化合物，该化合物是具有大环分子结构的小分子激酶抑制剂，还涉及包含该化合物的药物组合物以及该化合物的治疗用途，

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201980006719.7A 2018-01-30 2019-01-24 具有大环分子结构的化合物及其用途 Active CN111511749B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810088895.7 2018-01-30
CN201810088895 2018-01-30
PCT/CN2019/072950 WO2019149131A1 (zh) 2018-01-30 2019-01-24 具有大环分子结构的化合物及其用途

Publications (2)

Publication Number Publication Date
CN111511749A true CN111511749A (zh) 2020-08-07
CN111511749B CN111511749B (zh) 2022-02-08

Family

ID=67477914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980006719.7A Active CN111511749B (zh) 2018-01-30 2019-01-24 具有大环分子结构的化合物及其用途

Country Status (3)

Country Link
CN (1) CN111511749B (zh)
TW (1) TW201932472A (zh)
WO (1) WO2019149131A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156813A (zh) * 2018-02-13 2019-08-23 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CN110386944A (zh) * 2018-04-16 2019-10-29 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途
US12129258B2 (en) 2018-04-25 2024-10-29 Primegene (Beijing) Co., Ltd Diaryl macrocyclic compound and pharmaceutical composition, and use thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110627812B (zh) 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
WO2021042890A1 (zh) * 2019-09-04 2021-03-11 罗欣药业(上海)有限公司 杂环化合物及其作为Trk激酶抑制剂的应用
CN110804059B (zh) * 2019-09-30 2024-03-12 郑州泰基鸿诺医药股份有限公司 氨基甲酸酯类化合物、药物组合物及其应用
IL293458A (en) * 2019-12-03 2022-07-01 Turning Point Therapeutics Inc Macro rings for use in the treatment of the disease
AU2021268664A1 (en) * 2020-05-05 2022-10-20 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
EP4146205A4 (en) * 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHER-BASED CHEMOTHERAPY AGENTS
CN114213329B (zh) * 2021-12-29 2023-08-22 中国农业科学院兰州畜牧与兽药研究所 一种芳基吡唑类化合物的制备方法
CN114181152B (zh) * 2021-12-29 2023-08-22 中国农业科学院兰州畜牧与兽药研究所 一种芳基吡唑类药物中间体的制备方法
WO2024032390A1 (zh) * 2022-08-09 2024-02-15 苏州朗睿生物医药有限公司 一种大环三氮唑衍生物及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264736A (zh) * 2008-10-22 2011-11-30 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1，5-a]嘧啶化合物
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
CN106170289A (zh) * 2014-01-24 2016-11-30 Tp生物医药公司 作为蛋白质激酶的调节剂的二芳基巨环
WO2017004342A1 (en) * 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
WO2017075107A1 (en) * 2015-10-26 2017-05-04 Nanda Nisha Point mutations in trk inhibitor-resistant cancer and methods relating to the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264736A (zh) * 2008-10-22 2011-11-30 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1，5-a]嘧啶化合物
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
CN106170289A (zh) * 2014-01-24 2016-11-30 Tp生物医药公司 作为蛋白质激酶的调节剂的二芳基巨环
WO2017004342A1 (en) * 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
WO2017075107A1 (en) * 2015-10-26 2017-05-04 Nanda Nisha Point mutations in trk inhibitor-resistant cancer and methods relating to the same

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156813A (zh) * 2018-02-13 2019-08-23 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CN110156813B (zh) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CN110386944A (zh) * 2018-04-16 2019-10-29 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
CN110386944B (zh) * 2018-04-16 2021-10-29 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
US11358973B2 (en) 2018-04-16 2022-06-14 Shenzhen Targetrx, Inc. Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
US12129258B2 (en) 2018-04-25 2024-10-29 Primegene (Beijing) Co., Ltd Diaryl macrocyclic compound and pharmaceutical composition, and use thereof
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途

Also Published As

Publication number Publication date
TW201932472A (zh) 2019-08-16
WO2019149131A1 (zh) 2019-08-08
CN111511749B (zh) 2022-02-08

Similar Documents

Publication Publication Date Title
CN111511749B (zh) 具有大环分子结构的化合物及其用途
CN115335379B (zh) 含螺环的喹唑啉化合物
WO2022132914A1 (en) Prmts inhibitors
AU2021400942A9 (en) PRMT5 inhibitors
JP6404332B2 (ja) 新規な、ＮＩＫ阻害剤としての３−（１Ｈ−ピラゾール−４−イル）−１Ｈ−ピロロ［２，３−ｃ］ピリジン誘導体
EP3398950B1 (en) Novel kinase inhibitor against wild-type egfr and mutated egfr
EP3392245A1 (en) Novel egfr and alk dual inhibitor
JP6616411B2 (ja) 新規な、ｎｉｋ阻害剤としてのピラゾール誘導体
CN106488910A (zh) Kras g12c的抑制剂
EP3661935B1 (en) Substituted pyrazolopyrimidines useful as kinases inhibitors
EP3844166B1 (en) Substituted macrocycles useful as kinase inhibitors
CN116390728B (zh) 喹唑啉衍生物及其制备方法和用途
TW202035422A (zh) 作為ｃｄｋ抑制劑的大環化合物、其製備方法及其在醫藥上的應用
WO2024105553A1 (en) Bicyclic heterocycles and their use as wrn inhibitors
KR20170043546A (ko) 퀴나졸린 유도체
CA3130471C (en) Pan-raf kinase inhibitor and use thereof
US10173995B2 (en) Pyridine compounds used as PI3 kinase inhibitors
CN115141202A (zh) 嘧啶并吡嗪酮化合物及其用途
EP4006026A1 (en) Class of triaromatic compounds targeting bifunctional phosphorylation site of stat3 and applications thereof
CN114181212A (zh) 哒嗪酮类AhR抑制剂
CN103420906B (zh) 新型酪氨酸蛋白激酶抑制剂
CN107266468A (zh) 含吡唑啉结构的噻喃并嘧啶类化合物的制备及应用
WO2024067744A1 (zh) 杂环取代喹唑啉及其制备方法和应用
RU2792626C1 (ru) Новый ингибитор киназы pan-raf и его применение
EP4450504A1 (en) Heterocyclic compound having anti-tumor activity and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant